Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Data demonstrated favorable safety and local tolerability of ZORYVE ® (roflumilast) cream 0.15% in adults and children with atopic dermatitis ... tolerability data in scalp and body psoriasis ...

A second poster presentation shares results from the Phase 3 ARRECTOR trial that outlines improvements in patient-reported outcomes with investigational ZORYVE foam 0.3% compared with vehicle in ...

“While topical therapies are the first line of therapy for millions of people with atopic dermatitis ... based on the PDUFA for the treatment of scalp and body psoriasis, the potential for ...

cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and contraindications to topical treatments New patient reported outcome data for ...

“While topical therapies are the first line of therapy for millions of people with atopic dermatitis ... dermatological conditions including scalp and body psoriasis, AD, and alopecia areata.

A longitudinal multiomics analysis of a patient with multiple myeloma who developed peripheral T cell lymphoma after treatment with anti-BCMA CAR T cells and a GPRC5D-directed bispecific antibody ...

ITEN, Kenya—As dawn breaks over the sleepy town of Iten, its dusty tracks come alive with packs of runners keeping rhythm, often followed by cheerful children headed to school.